Chamber and committees

The Scottish Government does not hold this information. Public Health Scotland provide information through Drug and Alcohol Information System (DAISy) the national database that holds data about drug and alcohol services.

The DAISy initial assessments report tables, provide information on ketamine which is grouped into a larger ‘dissociatives’ category and presented at NHS Board of Residence level per financial year. Tables 4.4 and 4.5 relate to the drugs cohort and report on all drugs listed at assessment and main drug only; tables 5.9 and 5.10 are the same but for the ‘both drugs and alcohol’ cohort. These figures relate to the first assessment a person has had in each year, NHS Board and substance type, so do not represent individuals. Disclosure control has been applied so values are not available for every NHS Board. Data are available for financial years 2021-22 to 2024-25 inclusive.

The quarterly RADAR management information dashboard, presents monthly data for the main drug reported at assessment, by NHS Board of treatment, which includes specific data on ketamine (Chart 2: Main Drug). These data can be found on the ‘Service Indicators’ page and are for all assessments recorded in DAISy. The data include all assessments for drugs and both alcohol and drugs so are not equivalent to individuals. Data in the dashboard currently cover November 2020 – February 2026 and no data have been suppressed. Filters at the top of the page can be used to select the area and time period of interest, and there is a filter above the chart to select the drug of interest. To note that there is a minor issue with ‘Chart 1’ in the current version of the dashboard, which means that data for individual NHS Boards are not displayed. Chart 2 is unaffected and the issue will be corrected in the next release (July 2026).

There is currently no national collection of data on ketamine-induced bladder damage. The Scottish Government are ensuring that Alcohol and Drug Partnerships and specialist services take the needs of ketamine usage into account in commissioning and delivering acute care and aftercare services.

Data held by the Scottish Government on the number of NHS apprenticeships has been provided in the following tables. While this Management Information provides an indication of apprenticeship activity within NHS Scotland, the figures across years should be treated with caution because of the changes in collection method, coverage and definitions. The data records the number of individuals who have been recruited or started on an apprenticeship programme in the reporting year, rather than the total number of apprenticeships delivered.

Data for the total number of apprenticeships recruited is not held by the Scottish Government for 2016-2017 and there is no data for 2019-2020 to 2021-2022, as no annual Staff Governance Monitoring return was undertaken during COVID. Apprenticeship data is not yet available for 2024-25 or 2025-26 but will be collected via NHS Anchors Metrics.

The UK Advisory Council on the Misuse of Drugs (ACMD) recommended in their ketamine review of January 2026, that work on drug treatment should be collaborative with specialist urology, pain management, hepatology and gastroenterology services.

In Health Boards throughout Scotland, Urology departments have clinical guidance in assessment and multidisciplinary management of bladder symptoms related to ketamine use. Due to an increase in admissions of young people, Aberdeen Royal Infirmary Urology department has created a specialist 'ketamine bladder' clinic.

The Scottish Government are aware of a significant spike in ketamine harms - particularly among young people, and it is an integral part of our new Strategic Plan, to create further standards to ensure services can adapt to changing drug trends. It highlights the need for responsive and adaptive services, with improvement to treatment pathways in drug services, and connections to primary, acute and specialist settings.

Work is continuing at pace to establish the inquiry. Detailed Terms of Reference are currently being developed, informed by ongoing discussions with Professor Jay, and these will be published in due course.

I would also reiterate that it is not appropriate for Ministers to direct an independent inquiry Chair in relation to its duration or costs. Professor Jay has made clear her intention to deliver the inquiry at pace, while retaining the necessary flexibility to examine all areas within its remit. Decisions regarding the timing and frequency of the inquiry’s findings will be a matter for Professor Jay.

The Scottish Government published a review of clinical nurse specialist and nurse practitioner roles in Scotland in August 2021. Public Services Delivery Scotland is currently working on updating this report, focusing on education and professional development within clinical nurse specialist roles.

One of the recommendations from the report was achieved in May 2026, when Public Services Delivery Scotland published the first Clinical Nurse Specialist workforce statistical report since 2018.

The digitisation of records is managed operationally by individual Health Boards and GP practices, information on implementation of digitisation projects within each Health Board is not held centrally.

The GP IT Project team has a register (GPIT RP Phase Three Risks and Issues Log).The highest rated risks are currently amber.

This information is not held centrally by the Scottish Government.

Scottish Government wants people diagnosed with cancers such as leukaemia to be treated as close to home as clinically possible. We continue to work with NHS Boards, to limit the need for travel where possible and clinically appropriate. This includes through increased use of digital and technological solutions such as Near Me, to improve flexibility of care.

However, some treatments require delivery in specialist centres to ensure the best outcomes. Where travel is necessary, patients in rural areas should be fully supported in accessing these.

The Scottish Government provides the overall guidance to NHS Boards for patient travel expenses reimbursement, with NHS Boards responsible for local arrangements. In addition, the Highlands and Islands Travel Scheme (HITS) reimburses the travel costs of eligible patients who need to travel longer distances for care.

We are also committed to supporting patients to deal with the financial, emotional, and physical health effects of cancer, including those living in a rural area. We are currently working in partnership with Macmillan to deliver the Transforming Cancer Care Programme, which ensures that people affected by cancer in Scotland have access to a specialist key support worker, who can provide and signpost to emotional, financial, and practical support.